van der Heijde, Désirée http://orcid.org/0000-0002-5781-158X
Gensler, Lianne S
Deodhar, Atul
Baraliakos, Xenofon http://orcid.org/0000-0002-9475-9362
Poddubnyy, Denis http://orcid.org/0000-0002-4537-6015
Kivitz, Alan
Farmer, Mary Katherine
Baeten, Dominique
Goldammer, Nadine
Coarse, Jason
Oortgiesen, Marga
Dougados, Maxime
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study (Results)
https://doi.org/10.1136/annrheumdis-2020-216980
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2018-eular.7889
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.323
POS0919 BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1840
POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.156
OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6607
POS0938 MAINTENANCE OF RESPONSE TO BIMEKIZUMAB OVER 3 YEARS OF TREATMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POST HOC ANALYSES FROM THE BE AGILE STUDY AND ITS OPEN-LABEL EXTENSION
https://doi.org/10.1136/annrheumdis-2022-eular.2138
Documents that mention this clinical trial
POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786
POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836
POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2416
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760
AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2758
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Documents that mention this clinical trial
POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786
POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562
Axial spondyloarthritis: new advances in diagnosis and management
https://doi.org/10.1136/bmj.m4447
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760
OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2441
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Documents that mention this clinical trial
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study (Results)
https://doi.org/10.1136/annrheumdis-2020-216980
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2018-eular.7889
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.323
POS0919 BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1840
POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.156
OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6607
POS0938 MAINTENANCE OF RESPONSE TO BIMEKIZUMAB OVER 3 YEARS OF TREATMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POST HOC ANALYSES FROM THE BE AGILE STUDY AND ITS OPEN-LABEL EXTENSION
https://doi.org/10.1136/annrheumdis-2022-eular.2138